Can a patient who had angioedema while taking losartan (an angiotensin receptor blocker) be prescribed lisinopril (an angiotensin-converting enzyme inhibitor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, lisinopril should NOT be prescribed to a patient who had angioedema while taking losartan.

A patient with ARB-induced angioedema should avoid ACE inhibitors entirely due to the risk of cross-reactivity and potentially life-threatening recurrence.

Clinical Reasoning

The situation you're describing is actually the reverse of the more commonly discussed scenario. The guidelines and evidence primarily address switching FROM ACE inhibitors TO ARBs after angioedema, not the other way around. However, the underlying mechanism and cross-reactivity risk applies bidirectionally.

Why This Is Contraindicated

Lisinopril is absolutely contraindicated in patients with a history of angioedema, regardless of the causative agent 1. The FDA drug label explicitly states: "Lisinopril is contraindicated in patients with a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor" and importantly adds "hereditary or idiopathic angioedema" 1.

While the guidelines specifically warn about ARB use after ACE inhibitor-induced angioedema 2, 3, the mechanism of angioedema with both drug classes involves the renin-angiotensin system and bradykinin pathway. Although ARBs were thought not to affect bradykinin degradation (unlike ACE inhibitors), clinical evidence demonstrates that angioedema can occur with ARBs 4, 5, 6, 7.

The Evidence on Cross-Reactivity

The ACC/AHA guidelines state: "Although ARBs may be considered as alternative therapy for patients who have developed angioedema while taking an ACEI, there are a number of patients who have also developed angioedema with ARBs and extreme caution is advised" 2, 3. This bidirectional risk is critical.

Research confirms that:

  • Approximately 2-17% of patients with ACE inhibitor-induced angioedema will experience recurrence with ARBs 8
  • Multiple case reports document angioedema with losartan, including in patients who previously had ACE inhibitor-induced angioedema 5, 6, 7, 9
  • Almost half of patients with ARB-associated angioedema had previously developed angioedema with ACE inhibitors 6

The Reverse Scenario (Your Question)

If a patient developed angioedema on an ARB (losartan), switching to an ACE inhibitor (lisinopril) carries even greater risk because:

  1. ACE inhibitors have a HIGHER incidence of angioedema than ARBs (occurs in <1% with ACE inhibitors vs. much less frequent with ARBs) 2, 3
  2. ACE inhibitors directly inhibit bradykinin degradation, making the mechanism more potent 8
  3. The patient has already demonstrated susceptibility to renin-angiotensin system blocker-induced angioedema

What To Do Instead

Alternative antihypertensive agents should be selected from different drug classes:

  • Calcium channel blockers (amlodipine, diltiazem)
  • Thiazide diuretics (chlorthalidone, hydrochlorothiazide)
  • Beta-blockers (if indicated)
  • Direct vasodilators or other classes depending on comorbidities

10 provides comprehensive alternatives for blood pressure management.

Critical Pitfalls to Avoid

  1. Never assume the angioedema was unrelated to the ARB - even if it occurred months after initiation (can occur from 24 hours to 16 months after starting) 5
  2. Do not rechallenge with any renin-angiotensin system blocker - the risk of recurrence is unacceptable given safer alternatives exist
  3. Black patients have higher risk of angioedema with both drug classes 2, 3
  4. Document the angioedema history prominently in the medical record to prevent future prescribing errors

Because angioedema can be life-threatening with airway involvement, the principle of "first, do no harm" mandates avoiding all drugs in this class when a patient has demonstrated susceptibility.

References

Research

Angioneurotic edema attributed to the use of losartan.

Archives of internal medicine, 1998

Research

Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.

Archives of otolaryngology--head & neck surgery, 2004

Research

Losartan-induced Angioedema: A Case Report and Review of Literature.

Journal of community hospital internal medicine perspectives, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.